NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

Study Summary

This is a single-arm, open-label, multi-center, Phase 1 study to determine safety and tolerability of an experimental therapy called NKX101 (allogeneic CAR NK cells targeting NKG2D ligands) in patients with relapsed/refractory AML or intermediate, high and very high risk relapsed/refractory MDS.

Conditions

Relapsed/Refractory AML AML, Adult MDS Refractory Myelodysplastic Syndromes

Interventions / Drugs

NKX101 - CAR NK cell therapy

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment61 participants

Primary Completion—

Lead SponsorNkarta, Inc.

Data Retrieved2026-04-11 04:22:44.430470+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.